These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27128606)

  • 1. Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers.
    Xu J; Gray F; Henderson A; Hicks K; Yang J; Thompson P; Oliver J
    Clin Pharmacol Drug Dev; 2014 May; 3(3):170-8. PubMed ID: 27128606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P
    Juif PE; Dingemanse J; Winkle P; Ufer M
    Clin Transl Sci; 2021 Jan; 14(1):143-147. PubMed ID: 32860737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ; Hartung JP; Peach RJ; Boehm MF; Rosen H; Smith H; Brooks JL; Timony GA; Olson AD; Gujrathi S; Frohna PA
    J Clin Pharmacol; 2017 Aug; 57(8):988-996. PubMed ID: 28398597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigation of Initial Cardiodynamic Effects of the S1P
    Juif PE; Hoch M; Vaclavkova A; Krause A; Bush J; Dingemanse J
    J Clin Pharmacol; 2017 Mar; 57(3):401-410. PubMed ID: 27558098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.
    Brossard P; Scherz M; Halabi A; Maatouk H; Krause A; Dingemanse J
    J Clin Pharmacol; 2014 Feb; 54(2):179-88. PubMed ID: 24408162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ; Hartung JP; Tompkins CA; Frohna PA
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):634-640. PubMed ID: 29125718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy Subjects.
    Juif PE; Baldoni D; Reyes M; Wilbraham D; Febbraro S; Vaclavkova A; Hoch M; Dingemanse J
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of ponesimod, a selective S1P₁ receptor modulator, after uptitration to supratherapeutic doses in healthy subjects.
    Hoch M; D'Ambrosio D; Wilbraham D; Brossard P; Dingemanse J
    Eur J Pharm Sci; 2014 Oct; 63():147-53. PubMed ID: 25046167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute Bioavailability of Ponesimod, a Selective S1P
    Boehler M; Juif PE; Hoch M; Dingemanse J
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):129-134. PubMed ID: 26883438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.
    Brossard P; Derendorf H; Xu J; Maatouk H; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2013 Dec; 76(6):888-96. PubMed ID: 23594176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults.
    Lee CA; Schreiber S; Bressler B; Adams JW; Oh DA; Tang YQ; Zhang J; Komori HK; Grundy JS
    Clin Pharmacol Drug Dev; 2024 May; 13(5):534-548. PubMed ID: 38345530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
    Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
    Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers.
    Okour M; Gress A; Zhu X; Rieman D; Lickliter JD; Brigandi RA
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1088-1099. PubMed ID: 30950565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects.
    Scherz MW; Brossard P; D'Ambrosio D; Ipek M; Dingemanse J
    J Clin Pharmacol; 2015 Jun; 55(6):688-97. PubMed ID: 25612299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products.
    Zhang S; Jin S; Griffin C; Feng Z; Lin J; Baratta M; Brake R; Venkatakrishnan K; Gupta N
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1028-1043. PubMed ID: 34118178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.
    Hirawat S; Welch EM; Elfring GL; Northcutt VJ; Paushkin S; Hwang S; Leonard EM; Almstead NG; Ju W; Peltz SW; Miller LL
    J Clin Pharmacol; 2007 Apr; 47(4):430-44. PubMed ID: 17389552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration.
    Milton KA; Scott NR; Allen MJ; Abel S; Jenkins VC; James GC; Rance DJ; Eve MD
    J Clin Pharmacol; 2002 May; 42(5):528-39. PubMed ID: 12017347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.